Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), it sends a ...
TransCode Therapeutics (RNAZ) Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s stockholders on November 22, 2024, and is intended to ...
Transcode Therapeutics, Inc. (RNAZ) stock has reached a 52-week low, trading at $1.7, marking a significant downturn for the biotech company. With a market capitalization of just $1.25 million, ...
First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TransCode Therapeutics ( (RNAZ)) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results